Open AccessSKIN B-CELL LYMPHOMAS: 20 YEARS EXPERIENCE IN OBSERVATION AND TREATMENT
Author(s) -
I. Lamotkin,
A. O Rukavitsyn,
В В Гладько,
Г. Н. Тарасенко,
В. Н. Волгин,
Yu. G. Tarasenko
Publication year - 2017
Publication title -
rossijskij žurnal kožnyh i veneričeskih boleznej
Language(s) - English
Resource type - Journals
eISSN - 2412-9097
pISSN - 1560-9588
DOI - 10.18821/1560-9588-2017-20-5-260-266
Subject(s) - medicine , lymphoma , chop , marginal zone , radiation therapy , chemotherapy , pathology , rituximab , marginal zone b cell lymphoma , b cell , dermatology , immunology , antibody
Authors observed 18 patients with cutaneous B-cell lymphomas (B-CLS): primary cutaneous follicle center lymphoma (PCFCL) (44,45%), primary diffuse large B-cell lymphoma (B-CLL) (44,45%), cutaneous marginal zone B-cell lymphoma (CMZL) (11,1%). Features of cutaneous marginal zone B-cell lymphoma are: appearance of multiple spots; identification of diagnosis in stages T2aN0M0; treatment - excision or laser destruction; frequent recurrence do not affect prognosis. Features of primary cutaneous follicle center lymphoma are: appearance of single node; identification of diagnosis in stages T1aN0M0 and T2aN0M0; treatment - excision, can be also combined with radiotherapy. Features of primary diffuse B-CLL are: appearance of multiple spots; identification of diagnosis in stages T3bN0M0, T1aN1M0 and T2bN2M0; disease is aggressive; treatment is a local radiotherapy, interferon alpha intralesional, chemotherapy according to schemes CHOP, COP and R-CHOP, photodynamic therapy is possible.